HepQuant Test Inventor and Founder Doctor Gregory T. Everson Accepts Position of CEO
DENVER (July 1, 2017) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that its liver test inventor, Dr. Greg Everson, who recently retired from the Division of Gastroenterology and Hepatology at the University of Colorado School of Medicine in Denver, CO, has accepted the position of CEO, HepQuant LLC.
As CEO and Managing Member of HepQuant, LLC, a company he founded in 2007 with a small group of investors, Dr. Everson is encouraged by the the company’s recent business and operational progress. “We have recently moved past some key milestones such as our Investigational Device Exemption (“IDEs”) for the HepQuant SHUNT™ Liver Diagnostic Kit for use in a phases of clinical studies,” said Dr. Everson. “This forward progress toward building out our business and increasing interest in our potential products tells me we are in the right space at the right time.”
After over twenty years of research, Dr. Everson founded HepQuant LLC with the purpose of bringing to the mass market, a better way to assess liver function versus previous and existing standards. “HepQuant intends to commercialize this novel technology for minimally invasive assessment of chronic liver disease. Our tests are designed to measure the global function and physiology of the liver, regardless of the cause of liver disease. A safe, well-tolerated test of global liver function could be the holy grail for chronic liver disease patients and their caregivers,” Everson said.
A member of the American College of Physicians, American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Society of Transplantation (AST), the International Liver Transplant Society (ILTS), Dr. Everson earned his MD degree from Cornell Medical College, New York, NY. He is recognized nationally and internationally and has authored over 300 original articles relating to liver disease.
About HepQuant
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
MEDIA CONTACT
Tom Kennedy
E: tkennedy@hepquant.com | M: (720) 507-4164